Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

Major bank drops bombshell on Fed interest-rate bets

View original at finance.yahoo.com
Major bank drops bombshell on Fed interest-rate bets After an especially bruising week of hot back-to-back inflation headlines, increasing uncertainties about the end of the Iran war’s energy shocks, and a flaccid state visit to China, the bond market’s outlook for a Fed interest-rate hike this year flexed…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The market-implied probability of a quarter-point Fed rate hike in 2026 is 50% as of May 15, up from 40% the previous day and from approximately 10% at the start of the year.

    60% confidence
  • March Core PCE (excluding food and energy) rose to 3.2% year over year, up from 2.9% in February.

    60% confidence
  • March headline PCE rose to 3.5% year over year, up from 2.8% in February, largely driven by energy costs.

    60% confidence
  • The 30-year Treasury yield topped the 5% threshold during the week of May 15, 2026.

    60% confidence
  • The FOMC will entertain rate hikes only in a world of bad choices: either allowing inflation to increase further and become entrenched, or accepting the risk that a policy adjustment could prove macroeconomically destabilizing.

    60% confidence
  • The April PCE inflation report due May 28 will remain elevated and reinforce expectations that the Fed keeps the benchmark Federal Funds Rate higher for longer.

    60% confidence
  • The Federal Open Market Committee is likely to strongly prefer a long-term hold stance to rate hikes in 2026.

    60% confidence
  • If the Fed begins hiking rates later in 2026 under new Chair Kevin Warsh, this would create downside risk to BNP Paribas's otherwise optimistic economic outlook.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com